However, despite convincing evidence indicating a pivotal role of IL-1 in the pathogenesis of myocardial inflammation and myocarditis-related systolic dysfunction, the use of IL-1 blocking agents has been only anecdotally reported in this clinical condition. The gene discussed is IL1A; the disease is inflammation.